Online Only Articles

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Institute for Cell Biology, Department of Immunology, Eberhardt Karls-University of Tübingen, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany;Associated Hematology Practice, Bad Kreuznach, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Vol. 102 No. 5 (2017): May, 2017 https://doi.org/10.3324/haematol.2016.152017